<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108688</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 209/2021</org_study_id>
    <nct_id>NCT05108688</nct_id>
  </id_info>
  <brief_title>Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache</brief_title>
  <official_title>Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache Following Obstetric Surgery Under Spinal Anesthesia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postdural puncture headache (PDPH) is a potential complication after spinal anesthesia caused&#xD;
      by traction on pain-sensitive structures from low cerebrospinal fluid pressure (intracranial&#xD;
      hypotension) following a leak of cerebrospinal fluid at the puncture site. Symptoms of this&#xD;
      condition include a bilateral frontal or occipital headache that is worse in the upright&#xD;
      position, along with nausea, neck pain, dizziness, visual changes, tinnitus, hearing loss, or&#xD;
      radicular symptoms in the arms.&#xD;
&#xD;
      This study will examine the efficacy of mirtazapine in in the treatment of PDPH after&#xD;
      obstetric surgery under spinal anesthesia and compared its efficacy with that of sumatriptan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of headache ((number of patients)(n),% of patients)</measure>
    <time_frame>72 hours after intervention (Day 0)</time_frame>
    <description>Incidence of headache ((number of patients)(n),% of patients) after 72 hours after intervention (Day 0)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Mirtazapine Therapy group (M group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan Therapy group (S group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group ( C group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Mirtazapine 30 mg tablet once daily for 3 successive days</description>
    <arm_group_label>Mirtazapine Therapy group (M group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Sumatriptan 50 mg tablet once daily for 3 successive days</description>
    <arm_group_label>Sumatriptan Therapy group (S group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily for 3 successive days.</description>
    <arm_group_label>Control group ( C group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I and II Patients.&#xD;
&#xD;
          -  Patients undergoing obstetric surgeries under spinal anesthesia. and complaining from&#xD;
             moderate-to-severe PDPH after 25G spinal needle puncture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the intervention or participation in the study.&#xD;
&#xD;
          -  Patient under age of 18 years old.&#xD;
&#xD;
          -  Psychiatric illness.&#xD;
&#xD;
          -  Patients with a history of ischemic heart disease, pregnancy-induced hypertension,&#xD;
             chronic hypertension, cardiac, vascular, liver or renal impairment.&#xD;
&#xD;
          -  Patients with a history of migraine.&#xD;
&#xD;
          -  Patients with known hypersensitivity to study drugs.&#xD;
&#xD;
          -  Patients currently using ergotamine, monoamine oxidase inhibitors, or selective&#xD;
             serotonin reuptake inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ibrahim Mamdouh Esmat</last_name>
    <phone>01001241928</phone>
    <email>ibrahim_mamdouh@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain-Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr.Ibrahim Mamdouh Esmat</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

